| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.057 | 0.4 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.052 | 0.4 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |